Your browser doesn't support javascript. This means that the content or functionality of our website will be limited or unavailable. If you need more information about Vinnova, please contact us.
You're using version {0} of the web browser {1}. This means that the content or functionality of our website may be limited or unavailable. We recommend that you upgrade your browser to optimise your experience of our website.
Melatonin MT2-Selective Agonists as a Novel Treatment for Fragile X Syndrome (FXS) and Phelan-McDermid Syndrome (PMS)
| Reference number | 2025-01795 |
| Coordinator | CTC Clinical Trial Consultants AB |
| Funding from Vinnova | SEK 2 169 764 |
| Project duration | January 2026 - January 2029 |
| Status | Ongoing |
| Venture | European Joint Programme on Rare Diseases |
| Call | International collaborations with preclinical therapy studies of rare diseases |
Last updated 18 December 2025
Reference number 2025-01795
